

1 **Cognitive “Omics”: Pattern-based Validation of Potential Drug Targets**

2 István Gyertyán^{1,2,3}

3 1. MTA-SE NAP B Cognitive Translational Behavioural Pharmacology Group

4 2. Department of Pharmacology and Pharmacotherapy, Semmelweis University

5 3. Institute of Cognitive Neuroscience and Psychology, Research Center for Natural
6 Sciences, MTA, Budapest, Hungary

7 Correspondence: gyertyan.istvan@med.semmelweis-univ.hu

8 Keywords: animal models; cognitive enhancers; memory and cognitive disorders;
9 translational validity

10 Abstract:

11 *Despite the abundance of cognitive enhancer mechanisms identified in basic research, drugs*
12 *approved for cognitive disorders are scarce and of limited efficacy. Although the so-called*
13 *“gold standard” animal assays are well suited to study fundamental learning processes, they*
14 *fail to predict clinical efficacy against complex and robust cognitive defects. Preclinical*
15 *validation of potential drug targets requires new approaches with higher translational value.*
16 *Here I propose a rodent cognitive test system that encompasses several learning paradigms,*
17 *each modelling a certain human cognitive domain. Cognitive deficits are brought about by*
18 *several impairing methods and a particular mechanism of action is tested on each defective*
19 *cognitive function. The outcome is a cognitive efficacy pattern which should then be matched*
20 *to the cognitive deficit patterns of the clinical disorders. The best fit will highlight the clinical*
21 *indication with the greatest chance for success.*

22

1 **The “translational gap”**

2 When a molecular entity is shown to be involved in a given cognitive function, a quasi-
3 obligatory conclusion at the end of the paper is highlighting its potential in the therapy of one
4 or the other cognitive disorder. It is a recognized attempt by the authors to connect their work
5 to obvious social benefits and thereby emphasize and enhance the importance of the study.
6 Regretfully, these prophetic statements cannot be taken on face value as “playing a role” in a
7 certain cognitive process may well not mean being a “hot spot” of intervention in defective
8 cognitive functions. These “promising” targets need further validation in order to become
9 suitable subjects of feasible industrial drug development projects.

10 As an example, take two “gold-standard” animal learning assays: scopolamine-induced
11 amnesia in the passive avoidance paradigm and delay-induced forgetting in the novel object
12 recognition task. A PubMed search run for these two methods up to 2015 resulted in 678 hits
13 for the former and 246 hits for the latter. The abstracts were scanned one by one for effective
14 procognitive mechanisms of action identified in the assays. Solely in these two methods 103
15 different modes of action were detected (Table 1). If one takes into consideration other
16 versions of these two paradigms and other popular cognitive assays (e.g. Morris water-maze,
17 social recognition/discrimination or fear conditioning) a realistic estimation for the number of
18 *potential* cognitive enhancer mechanisms already identified in animal tests totals in the
19 hundreds.

20 The large number of potential targets confronts the stark fact that only two types of drugs are
21 in clinical application for dementia and memory impairment: the acetyl-choline-esterase
22 (AchE) inhibitors [1] and an NMDA antagonist, memantine [2]. In some European countries a
23 third class, the so called racetams (piracetam, aniracetam, etc.) with unknown mechanism of
24 action are also in use for mild memory impairments. Unfortunately, the efficacy of currently
25 available medications is, at best, moderate [3,4]; the racetams are even not approved in many
26 countries due to lack of clinical evidence. Furthermore, even the “youngest” drug, memantine
27 was launched more than a decade ago (in 2003),and the AchE inhibitors already came to
28 market in the nineties, while the appearance of racetams dates back to the 1970s [5].

29 The increasingly tense unmet need has driven enormous R&D activity in the field, and yet,
30 the clinical development of new drugs has faced a 100% **attrition rate** (see Glossary) in the
31 past decade. Detailed statistics are published by Ref. [6] for the period 2002-2012 showing a
32 high, 92% attrition rate already in Phase 2 clinical trials, i.e. in the **proof-of-concept studies**.

1 The overall success rate among AD drug-candidates – owing to the launch of memantine –
2 was, however, slightly different from zero (0.4%) in this period.

3 This long standing failure has slowly but surely led to a general devaluation of animal models
4 [7,8] and forced many pharma companies to withdraw from preclinical research and
5 development in CNS disorders [9].

6 The disappointment has not been confined to the industrial R&D. The European flagship
7 research and innovation program, Horizon 2020 consistently avoids funding of animal
8 research in its health domain (the ban is sometimes explicit); while molecular, IT and clinical
9 methodology are most welcome

10 (http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016_2017/main/h2020-wp1617-health_en.pdf/).

11 A

12 The aim of this article is to propose a preclinical approach, as a possible way out from the
13 current situation, by which the clinical success rate could be increased. First, factors
14 underlying the translational gap will be briefly analysed together with discussing the attempts
15 made so far to remediate the problem. Then a proposal will be put forward for a rodent
16 cognitive test battery with increased predictive power for the clinical efficacy of putative
17 cognitive enhancers. Finally, some related drug development issues will be discussed and
18 emerging feasibility questions will be raised.

19 **Causes of 'target-indication mismatch'**

20 Animal models thus detected a large number of false positive compounds which later failed in
21 the clinic. Ineffectiveness due to insufficient ADME properties (e.g. poor absorption,
22 metabolic vulnerability, low brain penetration, etc.) has gradually faded away as an attrition-
23 factor in the last 20 years [10] as the pharma industry successfully invested a lot of effort into
24 properly designing the physico-chemical parameters critical in shaping the ADME character
25 of the candidate molecules [11] and applying biomarker studies checking the presence/action
26 of the compound on the target. For example, PET studies demonstrated that histamine H₃
27 receptor antagonists and serotonin 5-HT₆ receptor antagonists occupied their respective
28 receptors to a high degree in humans [12,13] at doses where they produced mild or no effect
29 on cognitive performance in patients [14,15].

30 Thus, the major factor responsible for the missing efficacy must have been the
31 inappropriate/invalid modes of action of the compounds. This invalidity is the direct result of
32 insufficient and inappropriate target validation work, both in human and in animal studies,

1 preceding the clinical trials. The former would be even more important than the latter, but it is
2 not the subject of this paper.

3 Concerning preclinical validation, ample literature deals with the possible causes of the
4 missing predictive power of animal studies. One part of the critiques relates to the **external**
5 **validity** of the assays, i.e. *what type* of animal paradigms are used; the other part relates to
6 their **internal validity**, i.e. *how* these tests are carried out [16,17,18,19,20,21, 72]. Regarding
7 the latter, several shortcomings in methodology corrupting the reliability, reproducibility and
8 robustness of the results have been identified, such as statistically underpowered study design,
9 lack of randomization and blinding, inappropriate (use of) statistics, publication bias, just to
10 name a few. For remediation of the defects in internal validity several guidelines and
11 recommendations have been set forth [17,19,22,23,24].

12 The thoroughly analysed internal validity defects, however, do not account for the whole
13 extent of the translational gap. In cognitive enhancer research there are several modes of
14 actions, e.g. muscarinic M₁ agonists, histamine H₃ antagonists, serotonin 5-HT₆ antagonists
15 and nicotinic $\alpha 7$ agonists which have been shown to exert cognitive improving effects on
16 many types of impaired cognitive functions, in several different learning paradigms and with
17 more than a dozen compounds of each type [25,26,27,28]. While a part of the animal studies
18 may be put aside because of methodological deficiencies, the recurrent replication of some
19 findings in certain assays with different compounds, in different labs and with different
20 methodical variants did, indeed, lend the image of reproducibility and validity to the results.
21 This widespread procognitive activity raised non groundless expectations about their clinical
22 potential and all the four underwent extensive clinical investigations [29,30,31,32]. Yet, none
23 of them has managed so far to show up a successful Phase III trial on cognitive symptoms.

24 Clearly, there should also be problems with the external validity of the models used. Various
25 fashionable cognitive assays have emerged in the literature, like the passive avoidance test in
26 the nineties, or the novel object recognition test in the first decade of this millennium (Figure
27 S1). These assays gain popularity because they are simple, rapid, and involve elementary
28 cognitive functions well suited for studying fundamental learning and memory processes. By
29 producing lots of valuable data on cognition itself, these assays then became a kind of “gold
30 standard” in the field. Indeed, when considering the massive preclinical evidence for the
31 procognitive efficacy of the above mentioned targets, the reproduced findings are in large part
32 coming from these types of assays [26,27,28,33].

1 In industrial R&D, a consequence has been the acceptance of the – otherwise erroneous –
2 concept that checking the efficacy of potential novel cognitive enhancer drugs in the actual
3 gold standard assay is necessary and at the same time sufficient to provide predictions for
4 clinical effectiveness. Experience shows, however, what is a good model for basic research
5 may not be a good one for target validation [73,74]. First, the elementary cognitive functions
6 which are investigated in these assays do not model the complex cognitive domains affected
7 by the human disease [34,72,75]. Second, learning performance of the animals is usually
8 impaired by relatively mild interventions e.g. a single scopolamine dose or long delay, which
9 cannot, again, model the robust and multiple cognitive deficits characterising a clinical
10 syndrome [73,75].

11 This dichotomy between assays of basic research on one hand and disease models required for
12 target validation on the other [73,74], is nicely exemplified by the fact that even the
13 terminology was, for a long time, substantially different in animal versus clinical cognitive
14 research. While animal terminology largely classified cognitive functions by the *type of the*
15 *learning task* (operant vs pavlovian or aversive vs appetitive conditioning, spatial or non-
16 spatial learning, cue- or context-induced response, etc.), human terminology mainly used
17 words describing the *memory-type* under study (**declarative** vs **procedural** or **semantic** vs
18 **episodic** memory, dysexecutive syndrome, **theory of mind**, etc.). This literal translational
19 problem (which clearly reflects fundamentally different approaches), also contributed to the
20 discrepant outcomes in animal learning paradigms and in clinical cognitive trials.

21 Fortunately, in the past decade there has been a clear move on behalf of animal researchers
22 toward approaching the human terminology and classification. The well-known initiatives like
23 **MATRICES** [35] and **CNTRICS** [36] attempted to map and match the clinical symptoms to
24 animal paradigms. Further on, detailed analyses were carried out to select the most
25 appropriate animal models of several human cognitive domains, e.g. **social cognition** [37],
26 **working memory** [38]; executive control [39], attention [40]. [The primary criteria for model](#)
27 [selection were cognitive and neurobiological construct validity; the former referring to the](#)
28 [ability of the paradigm to specifically measure the targeted cognitive process; the latter](#)
29 [meaning the involvement of homologous neural circuits in human subjects and animals](#) [36].

30 However, potential cognitive enhancer molecules should not simply be tested in models of
31 human cognitive functions, but, instead, in models of *defective* human cognitive functions.
32 Therefore, validity of any animal model essentially and critically depends on the construct of
33 cognitive deficiency. In other words: on how impaired performance is brought about.

1 Single dose pharmacological treatment or increased task difficulty may well be criticized in
2 this respect. Notwithstanding that acute scopolamine can powerfully disrupt cognitive
3 performance in many learning tasks (see the review of Ref. [41]), its effect is often not
4 cognition-specific [75] and can be abolished by a single type of pharmacological action, e.g.
5 by increasing the endogenous acetylcholine level. Acetylcholine-esterase inhibitors, which
6 directly produce this effect, show modest potency in early AD [3], but not in other disorders.
7 If the assumptions hold true that both histamine H₃ and serotonin 5-HT₆ antagonists act, at
8 least in part, via indirectly increasing acetylcholine release as a final common pathway
9 [76,77], then not much better efficacy can be expected from these types of compounds than
10 that shown by the AChE inhibitors; neither in terms of magnitude nor of cognitive domains or
11 patient subgroups. Furthermore, if the broad procognitive activity of the compounds typically
12 manifest against scopolamine-induced impairments, then their effects may result from a
13 simple pharmacological interaction that is independent from the cognitive function being
14 studied. It is unlikely that a single mechanism would equally improve diverse cognitive
15 deficits. Assays relying on increased task difficulty, such as the natural forgetting paradigm in
16 the novel object or social recognition tasks, suffer from the discrepancy that increasing the
17 normal learning/memory performance in healthy animals presumes some mobilizable
18 cognitive reserve, which may not be available in an ill, thereby functionally corrupted brain.

19

20 **Proposal for a rodent cognitive test battery for target validation**

21 If an animal model is intended to be predictive for the human situation, then it should model
22 as closely as possible the human cognitive task and should conform to the human
23 terminology. Therefore, instead of memory tests whose highest values are simplicity and easy
24 measurability (like passive avoidance or novel object recognition), assays with higher
25 therapeutic relevance are needed. These are usually more complex and often time consuming
26 paradigms. The proposed test battery includes animal assays intended to model the human
27 cognitive domains (Table 2). These domains are selected from the 12 domains specified in the
28 review of Ref. [34] to characterize the cognitive deficit patterns of nine psychiatric disorders
29 (schizophrenia, depression, bipolar disorder, autistic spectrum disorders, attentional deficit-
30 hyperactivity disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress
31 disorder, generalized anxiety disorder) and two neurodegenerative diseases (Parkinson's
32 disease and Alzheimer's disease). The list can be considered fairly comprehensive and
33 covering the full spectrum of cognitive symptoms; and as such, appropriate and sufficient for

1 target validation. Verbal memory and language use are obviously dropped out from the list,
2 but the other functions can be studied in animals, too. The animal assays suggested for
3 modelling the human functions (Table 2) were chosen partly on the basis of MATRICS and
4 CNTRICS recommendations (working memory, social cognition, executive function,
5 attention), partly by our own judgement. The test list is primarily of illustrative nature; it
6 should by no means be considered exclusive or complete. Many of its items can be replaced
7 by equivalent alternatives, and some of the domains can be further broken down to
8 subcomponents or more specific assays may be constructed for one or the other domain. For
9 example, for modelling **semantic** and **episodic memory**, two different maze-learning
10 paradigms are suggested in Table 2, based on the theory that these cognitive capabilities
11 evolutionary evolved from **allocentric** and **egocentric navigation**, respectively [42].
12 However, for episodic memory, there exist several well elaborated and more specific animal
13 assays in the literature [43,44,45,46], which could also be used here. Another example for
14 tailoring the list to the needs (and conviction) of the user: if someone wants to go beyond
15 simple social recognition in the social cognition domain and try to approximate the ‘**theory of**
16 **mind**’ function, a social cooperation paradigm could be included.

17 However, switching to animal models better mimicking the human cognitive domains is just
18 the first step toward a predictive model-system. Modelling cognitive *deficits* (i.e. deteriorating
19 cognitive functions) is the main challenge. The cognitive deficiency construct to be
20 established depends on whether we want **disease modifying** or **symptomatic treatment** (see
21 Box 1), as the two impose different requirements on the model [73]. The former approach
22 requires disease models, which – in the ideal case – produce all or most of the cognitive
23 symptoms of the disorder by reproducing the pathological process. The latter approach works
24 with symptom models, which are unrelated to the disease process (e.g. do not require
25 neurodegeneration in the background) and constructed to produce defects in distinct cognitive
26 symptoms. The current proposal focuses on the symptomatic approach but can accommodate
27 the disease modifying one, too.

28 Defective cognitive performance can be brought about by several means: pharmacological
29 agents, cerebral lesions/activations (implying optogenetic/chemogenetic methods as well),
30 stressors, modulation of gene expression, old age, increasing task difficulty or selecting low
31 performers of the population – all may yield low cognitive outcome amenable for
32 improvement. Nevertheless, in lack of exact knowledge on or deliberately being unrelated to
33 the pathomechanism of the given disease (as in case of symptomatic treatment) no distinct

1 impairing intervention can be considered as the most “appropriate” or “predictive” (see again
2 the failure of the scopolamine-induced amnesia models in predicting clinical efficacy or the
3 critique on the PCP impairment in Box 1). On the other hand, each type of impaired cognitive
4 state holds utilizable information content thus bears a *certain extent* of relevance to the human
5 cognitive deficit. Therefore, to get a better prediction on the expected human efficacy of a
6 putative enhancer mechanism it should be tested against several impairing methods. By doing
7 so, one can make a virtue of necessity and set up a practically applicable “rule of thumb”: the
8 more types of impairing methods against which the studied mechanism is effective the higher
9 the chance it will be effective against the cognitive defects – of otherwise unknown or
10 uncertain origin – in the target disease.

11 Consequently, multiple types of cognitive impairment is suggested in case of each cognitive
12 function, and a ‘cognitive domains x impairing methods’ matrix of models as test battery is
13 proposed to be used for clinical prediction (Figure 1, Key Figure).

14 Although in principle each model could be operated as a separate experiment, – i.e. each
15 testing of a compound could be done in a new cohort of naive animals freshly taught for the
16 task and then impaired in performance, – it is not recommended to follow for several reasons.
17 Comprehensive validation of a target in this way would require an unnecessary large number
18 of animals, take unreasonably long time and bring about adversely high variability in the
19 results. In addition, such testing procedure would have low clinical relevance, too.

20 To establish a more coherent methodical environment, be suited for the 3R principles, and
21 also for mimicking the human clinical circumstances, several cognitive tasks representing
22 different cognitive domains should be taught to the same set of animals, thereby creating a
23 population with “widespread knowledge”. This process may take several weeks. These
24 animals are then transformed to a “patient” population by exposing them to a certain
25 impairment method. To increase the human relevance of the induced cognitive deficits, long
26 term interventions should be applied whenever possible, e.g. subchronic pharmacological
27 treatments, stress exposure or lesion/activation. Aging can be considered as a natural way of
28 impairment. Note, that with some impairing methods like constitutive genetic modifications
29 or perinatal treatments the patient population is created “in advance” of teaching and
30 performing the cognitive tasks. Many specific disease models fit into this category. The
31 “patient” population then can subsequently be subjected to one or more improving
32 interventions. Here also, long term treatment is desirable to model the clinical situation. If the
33 applied impairment is reversible, i.e. the memory/learning defects resolve after cessation of

1 the impairing intervention, further impairment can be sequentially performed in the same
2 cohort of animals for initiating another “drug trial”. This is the case, for example, with
3 increasing task difficulty, certain stressors or pharmacological treatments. The outcome of
4 such testing allows not only to judge the efficacy of a certain mechanism of action but the
5 cognitive enhancer pattern may help in selecting the proper target patient population in the
6 clinic (see below).

7

8 **Patient population selection process**

9 Neurological and psychiatric disorders show diverse patterns of defective cognitive
10 functioning [34], and this pattern-specificity may require compounds with different mode of
11 actions. The traditional way of finding “the right molecule for the right indication” is the one
12 where the target disease is fixed and the appropriate drug is searched for (“marketing-based
13 selection”). Adapting this approach to target validation in the above system would mean that
14 the potential targets are tested in a simplified system containing only those learning/memory
15 paradigms which are relevant for the chosen disease. The smaller set of assays enables higher
16 testing turnover and lower running costs. However, targets potentially effective in other
17 indications may be missed by this approach. Further, and most importantly, finding the valid
18 target, i.e. one which satisfactorily fits the desired activity pattern may take quite a long time.

19 By contrast, the above described pattern-based validation offers an alternative way of
20 achieving “the right molecule for the right indication” fit. With this approach, the target
21 disease is not fixed in advance, but is rather determined at the end of the validation process.
22 The potential targets are tested in the full system until a mechanism with appealing efficacy
23 and activity pattern is found. Then the disease whose cognitive deficit pattern best matches
24 the cognitive activity pattern of the selected mechanism should be chosen as the target clinical
25 indication (“science-based selection”). Giving a simplistic example: if a certain mechanism of
26 action shows outstanding efficacy in assays measuring attention then it should be tried in
27 ADHD, whereas if it is more active in social cognition paradigms, then autism could be the
28 preferred choice. In this mechanism-based search for indications no promising target is lost
29 and validating a target for an indication may happen within a shorter time. For example, even
30 partial pattern matchings can be utilized if the aim is to relieve certain cognitive symptoms
31 regardless of the disease background. However, establishment of a larger set of models is
32 required which incurs higher running costs and lower testing turnover.

1 In both cases, a critical methodological factor is how the goodness of pattern-matching is
2 determined/calculated (see Outstanding Questions). Obviously, the better the fit the higher the
3 chance for clinical efficacy, but the exact criteria may be tailored to the needs and
4 expectations of the actual user.

5 The suggested pattern-based validation has analogous logic to that of the “*omics*” approaches,
6 therefore it may be termed “*cognomics*” (cognitive omics). According to the author’s
7 conviction, it will increase the probability of clinical success compared to the predictive
8 power of the so far applied approach which may be best described as “prove efficacy in the
9 gold standard model then run clinical trials in several disorders”. However, adopting the
10 *cognomics* approach will necessitate the changing of the drug discovery paradigm (see Box
11 2).

12

13 **Concluding Remarks**

14 Despite their seemingly weak predictive power, animal models can still be utilized in
15 preclinical drug discovery provided they meet external as well as internal validity criteria. The
16 target validating methodology should substantially change by approximating clinical studies
17 regarding patient population, treatment length and outcome measures. For the purpose of
18 predicting clinical efficacy, learning performance of animals should be examined in
19 paradigms really modelling the human cognitive functions. The validity of induced cognitive
20 *deficits* is a critical point either in the disease modifying or the symptomatic treatment
21 approach. A pattern-based validation is suggested to enhance the chance for clinical success.
22 It is worth considering that the clinical target population would be selected on the basis of the
23 merits of the validated targets and not on the basis of *a priori* marketing needs (see
24 Outstanding Questions). Finally, it is essential that the no man’s land between basic research
25 and industrial drug discovery be populated by target validating projects (the precompetitive
26 area). The Horizon 2020 bias should be corrected [54], and this type of research should be
27 actively supported in the future.

28

29 **Acknowledgements:** This study was funded by the Hungarian National Brain Research
30 Program (NAP), contract number KTIA_NAP_13-2014-0015. The author gratefully thanks to
31 Ferenc Kassai for his comments on the manuscript.

32

33 **Supplemental Information**

1 Supplemental Information associated with this article can be found at doi:

2 Conflict of Interest

3 The author declares no conflict of interest.

4 **References:**

- 5 1. O'Brien, J.T. et al. (2011) Clinical practice with anti-dementia drugs: a revised
6 (second) consensus statement from the British Association for Psychopharmacology.
7 *J. Psychopharmacol.* 25, 997-1019
- 8 2. Thomas, S.J. and Grossberg, G.T. (2009) Memantine: a review of studies into its
9 safety and efficacy in treating Alzheimer's disease and other dementias. *Clin.*
10 *Interventions Aging* 4, 367–377
- 11 3. Lindner, M.D. et al. (2008) Development, optimization and use of preclinical
12 behavioral models to maximise the productivity of drug discovery for Alzheimer's
13 Disease. In *Animal and translational models for CNS drug discovery: neurologic*
14 *disorders*. (McArthur, R.A. and Borsini, F., eds) pp. 93-158, Academic Press:Elsevier,
15 New York
- 16 4. Winblad, B. et al. (2007) Memantine in moderate to severe Alzheimer's Disease: a
17 meta-analysis of randomised clinical trials. *Dement. Geriatr. Cogn. Disord.* 24, 20–27
- 18 5. Giurgea, C. and Salama, M. (1977). "Nootropic drugs". *Prog. Neuropsychopharmacol.*
19 1, 235–247
- 20 6. Cummings, J. et al. (2014) Alzheimer's disease drugdevelopment pipeline: few
21 candidates, frequent failures. *Alzheimer's Res. Ther.* 6, 37
- 22 7. Geerts, H. (2009) Of mice and men. Bridging the translational disconnect in CNS drug
23 discovery. *CNS Drugs* 23, 915-926
- 24 8. Markou, A. et al. (2009) Removing Obstacles in Neuroscience Drug Discovery: The
25 Future Path for Animal Models. *Neuropsychopharmacology* 34, 74–89
- 26 9. Wegener, G. and Rujescu, D. (2013) The current development of CNS drug research.
27 *Int. J. Neuropsychopharmacol.* 16, 1687–1693
- 28 10. Kola, I. and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates?
29 *Nat. Rev. Drug Discov.* 3, 711-715

- 1 11. Keserű, G.M. and Makara, G.M. (2009). The influence of lead discovery strategies on
2 the properties of drug candidates. *Nat. Rev. Drug Discov.* 8, 203-212
- 3 12. Ashworth, S. et al. (2014) Unexpectedly high affinity of a novel histamine H3 receptor
4 antagonist, GSK239512, in vivo in human brain, determined using PET. *Brit. J.*
5 *Pharmacol.* 171, 1241–1249
- 6 13. Parker, C.A. et al. (2016) Human kinetic modelling of the 5-HT6 PET radioligand,
7 11C-GSK215083, and its utility for determining occupancy at both 5HT6 and 5HT2A
8 receptors by SB742457 as a potential therapeutic mechanism of action in Alzheimer’s
9 disease. *J. Nucl. Med.* DOI:10.2967/jnumed.115.162743
- 10 14. Grove, R.A. et al. (2014) A Randomized, Double-Blind, Placebo-Controlled, 16-Week
11 Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with
12 Mild-to-Moderate Alzheimer’s Disease. *Curr. Alzheimer Res.* 11, 47-58
- 13 15. Maher-Edwards, G. et al. (2015) Two randomized controlled trials of SB742457 in
14 mild-to-moderate Alzheimer’s disease. *Alzheimer’s Dement. TRCI* 1, 23-36
- 15 16. Gartner, J.P. (2014). The significance of meaning: why do over 90% of behavioral
16 neuroscience results fail to translate to humans, and what can we do to fix it? *ILAR J.*
17 55, 438-456
- 18 17. Steckler, T. (2015) Preclinical data reproducibility for R&D - the challenge for
19 neuroscience. *Psychopharmacol. (Berl)* 232, 317–320
- 20 18. van der Worp, H.B. et al. (2010) Can animal models of disease reliably inform human
21 studies? *PLoS Med.* 7, e1000245
- 22 19. Kilkenny, C. et al. (2009) Survey of the quality of experimental design, statistical
23 analysis and reporting of research using animals. *PLoS ONE* 4, e7824
- 24 20. Ioannidis, J.P.A. (2005) Why most published research findings are false. *PloS Med.* 2,
25 696–701
- 26 21. Sena, E.S. et al. (2010) Publication bias in reports of animal stroke studies leads to
27 major overstatement of efficacy. *PLoS Biol.* 8, e1000344
- 28 22. Muhlhausler, B.S. (2013) Whole Animal Experiments Should Be More Like Human
29 Randomized Controlled Trials. *PLoS Biol.* 11, e1001481

- 1 23. Festing, M.F.W. (2014) Randomized block experimental designs can increase the
2 power and reproducibility of laboratory animal experiments. *ILAR J.* 55, 472–476
- 3 24. Landis, S.C. et al. (2012) A call for transparent reporting to optimize the predictive
4 value of preclinical research. *Nature* 490, 187–191
- 5 25. Brioni, J.D. et al. (2011) Discovery of histamine H3 antagonists for the treatment of
6 cognitive disorders and Alzheimer’s disease. *JPET* 336, 38–46
- 7 26. Meneses, A. (2014) Memory formation and memory alterations: 5-HT6 and 5-HT7
8 receptors, novel alternative. *Rev. Neurosci.* 25, 325–356
- 9 27. Young, J.W. and Geyer, M.A. (2013) Evaluating the role of the alpha-7 nicotinic
10 acetylcholine receptor in the pathophysiology and treatment of schizophrenia.
11 *Biochem. Pharmacol.* 86, 1122–1132
- 12 28. Bubser, M. et al. (2012) Muscarinic receptor pharmacology and circuitry for the
13 modulation of cognition. In *Muscarinic Receptors. Handbook of Experimental*
14 *Pharmacology* 208 (Fryer, A.D. et al., eds) pp. 121-166, Springer-Verlag Berlin
15 Heidelberg
- 16 29. Wicke, K. et al. (2015) Investigational drugs targeting 5-HT6 receptors for the
17 treatment of Alzheimer’s disease. *Expert Opin. Investig. Drugs* 24, 1515-1528
- 18 30. Kubo, M. et al. (2015) Histamine H3 Receptor Antagonists for Alzheimer's Disease: A
19 Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *J.*
20 *Alzheimers Dis.* 48, 667-671
- 21 31. Beinat, C. et al. (2015) The therapeutic potential of $\alpha 7$ nicotinic acetylcholine receptor
22 ($\alpha 7$ nAChR) agonists for the treatment of the cognitive deficits associated with
23 schizophrenia. *CNS Drugs* 29, 529–542
- 24 32. Foster, D.J. et al. (2014) Activation of M1 and M4 muscarinic receptors as potential
25 treatments for Alzheimer’s disease and schizophrenia. *Neuropsychiatr. Dis. Treat.* 10,
26 183–191
- 27 33. Ellenbroek, B.A. and Ghiabi, B. (2015) Do histamine receptor 3 antagonists have a
28 place in the therapy for schizophrenia? *Curr. Pharmaceutical. Design* 21, 3760-3770

- 1 34. Millan, M.J. et al. (2012). Cognitive dysfunction in psychiatric disorders:
2 characteristics, causes and the quest for improved therapy. *Nat. Rev. Drug Discov.* 11,
3 141-168
- 4 35. Young, J.W. et al. (2009). Using the MATRICS to guide development of a preclinical
5 cognitive test battery for research in schizophrenia. *Pharmacol. Therapeut.* 122, 150–
6 202
- 7 36. Moore, H. et al. (2013). Harnessing cognitive neuroscience to develop new treatments
8 for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for
9 animal models. *Neurosci. Biobehav. Rev.* 37, 2087–2091
- 10 37. Millan, M.J. and Bales, K.L. (2013) Towards improved animal models for evaluating
11 social cognition and its disruption in schizophrenia: The CNTRICS initiative.
12 *Neurosci. Biobehav. Rev.* 37, 2166-2180
- 13 38. Dudchenko, P.A. et al. (2013) Animal models of working memory: A review of tasks
14 that might be used in screening drug treatments for the memory impairments found in
15 schizophrenia. *Neurosci. Biobehav. Rev.* 37, 2111-2124
- 16 39. Gilmour, G. et al. (2013) Measuring the construct of executive control in
17 schizophrenia: Defining and validating translational animal paradigms for discovery
18 research. *Neurosci. Biobehav. Rev.* 37, 2125-2140
- 19 40. Lustig, C. et al. (2013) CNTRICS final animal model task selection: Control of
20 attention. *Neurosci. Biobehav. Rev.* 37, 2099-2110
- 21 41. Klinkenberg, I. and Blokland, A. (2010) The validity of scopolamine as a
22 pharmacological model for cognitive impairment: A review of animal behavioral
23 studies. *Neurosci. Biobehav. Rev.* 34, 1307–1350
- 24 42. Buzsáki, G. and Moser, E.I. (2013) Memory, navigation and theta rhythm in the
25 hippocampal-entorhinal system. *Nat. Neurosci.* 16, 130-138
- 26 43. Fortin, N.J. et al. (2002) Critical role of the hippocampus in memory for sequences of
27 events. *Nat. Neurosci.* 5, 458–462
- 28 44. Kart-Teke, E. et al. (2006) Wistar rats show episodic-like memory for unique
29 experiences. *Neurobiol. Learn. Mem.* 85, 173–182

- 1 45. Roberts, W.A. et al. (2008) Episodic-like memory in rats: is it based on when or how
2 long ago? *Science* 320, 113–115
- 3 46. Zhou, W. and Crystal, J.D. (2011) Validation of a rodent model of episodic memory.
4 *Anim. Cogn.* 14, 325–340
- 5 47. Vorhees, C.V. and Williams, M.T. (2015) Reprint of “Value of water mazes for
6 assessing spatial and egocentric learning and memory in rodent basic research and
7 regulatory studies”. *Neurotoxicol. Teratol.* 52, 93–108
- 8 48. Talpos, J.C. et al. (2014) A touch-screen based paired-associates learning (PAL) task
9 for the rat may provide a translatable pharmacological model of human cognitive
10 impairment. *Pharmacol. Biochem. Behav.* 122, 97–106
- 11 49. Siegel, S.J. et al. (2013) Animal models and measures of perceptual processing in
12 schizophrenia. *Neurosci. Biobehav. Rev.* 37, 2092–2098
- 13 50. Bowers, M.E. and Ressler, K.J. (2015) An overview of translationally informed
14 treatments for posttraumatic stress disorder: animal models of pavlovian fear
15 conditioning to human clinical trials. *Biol. Psychiat.* 78, e15–e27
- 16 51. Markou, A. et al. (2013) Measuring reinforcement learning and motivation constructs
17 in experimental animals: Relevance to the negative symptoms of schizophrenia.
18 *Neurosci. Biobehav. Rev.* 37, 2149-2165
- 19 52. Monterosso, J. and Ainslie, G. (1999) Beyond discounting: possible experimental
20 models of impulse control. *Psychopharmacol. (Berl)* 146, 339–347
- 21 53. Luft, A.R. and Buitrago, M.M. (2005) Stages of motor skill learning. *Mol. Neurobiol.*
22 32, 205–216
- 23 54. Morris, R.G.M. et al. (2016) Consensus statement on European brain research - The
24 need to expand brain research in Europe – 2015. *Eur. J. Neurosci.* 44, 1919-1926
- 25 55. Barage, S.H. and Sonawane, K.D. (2015) Amyloid cascade hypothesis: Pathogenesis
26 and therapeutic strategies in Alzheimer's disease. *Neuropeptides* 52, 1–18
- 27 56. Musiek, E.S. and Holtzman, D.M. (2015) Three dimensions of the amyloid
28 hypothesis: time, space and ‘wingmen’. *Nat. Neurosci.* 18, 800-806

- 1 57. Foley, A.M. et al. (2015) Systematic review of the relationship between amyloid- β
2 levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease. *J.*
3 *Alzheimers Dis.* 44, 787-795
- 4 58. Zahs, K.R. and Ashe, K.H. (2010) 'Too much good news' – are Alzheimer mouse
5 models trying to tell us how to prevent, not cure, Alzheimer's disease? *Trends*
6 *Neurosci.* 33, 381–389
- 7 59. Sabbagh, J.J. et al. (2013) Animal systems in the development of treatments for
8 Alzheimer's disease: challenges, methods, and implications. *Neurobiol. Aging* 34,
9 169–183
- 10 60. Webster, S.J. et al. (2014) Using mice to model Alzheimer's dementia: an overview of
11 the clinical disease and the preclinical behavioral changes in 10 mouse models. *Front.*
12 *Genet.* 5, 88
- 13 61. Lannfelt, L. et al. (2014) Perspectives on future Alzheimer therapies: amyloid- β
14 protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease.
15 *Alzheimer's Res. Ther.* 6, 16-23
- 16 62. Schneider, L.S. et al. (2014) Clinical trials and late-stage drug development for
17 Alzheimer's disease: an appraisal from 1984 to 2014. *J. Intern. Med.* 275, 251–283
- 18 63. Herrup, K. (2015) The case for rejecting the amyloid cascade hypothesis. *Nat.*
19 *Neurosci.* 18, 794-799
- 20 64. Armstrong, R.A. (2014) A critical analysis of the 'amyloid cascade hypothesis'. *Folia*
21 *Neuropathol.* 52, 211-225
- 22 65. Sorrentino, P. et al. (2014) The dark sides of amyloid in Alzheimer's disease
23 pathogenesis. *FEBS Lett.* 588, 641–652
- 24 66. Olney, J.W. et al. (1999) NMDA receptor hypofunction model of schizophrenia. *J.*
25 *Psychiat. Res.* 33, 523-533
- 26 67. Neill, J.C. et al. (2010) Animal models of cognitive dysfunction and negative
27 symptoms of schizophrenia: focus on NMDA receptor antagonism. *Pharmacol. Ther.*
28 128, 419–432

- 1 68. Janhunen, S.K. et al. (2015) The subchronic phencyclidine rat model: relevance for the
2 assessment of novel therapeutics for cognitive impairment associated with
3 schizophrenia. *Psychopharmacol. (Berl)* 232, 4059–4083
- 4 69. Grayson, B. et al. (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced
5 cognitive deficit in the novel object recognition task in the rat. *Behav. Brain Res.* 184,
6 31–38
- 7 70. McLean, S.L. (2010) Effects of asenapine, olanzapine, and risperidone on
8 psychotomimetic-induced reversal-learning deficits in the rat. *Behav. Brain Res.* 214,
9 240–247
- 10 71. Paul, S.M. et al. (2010) How to improve R&D productivity: the pharmaceutical
11 industry's grand challenge. *Nat. Rev. Drug Discov.* 9, 203–214
- 12 72. Sarter, M. et al. (1992) Behavioral screening for cognition enhancers: from
13 indiscriminate to valid testing:Part I. *Psychopharmacol. (Berl)* 107, 144–159
- 14 73. Decker, M.W. (2006) Cognition Models and Drug Discovery. In *Animal Models of*
15 *Cognitive Impairment.* (Levin, E.D., Buccafusco J.J., eds) Chapter 16, CRC
16 Press/Taylor & Francis; Boca Raton (FL
- 17 74. Kimmelman, J. et al. (2014) Distinguishing between exploratory and confirmatory
18 preclinical research will improve translation. *PLoS Biology* 12, 12–15
- 19 75. Sarter, M. et al. (1992) Behavioral screening for cognition enhancers: from
20 indiscriminate to valid testing:Part II. *Psychopharmacol. (Berl)* 107, 461-463
- 21 76. Esbenshade, T.A. et al. (2008) The histamine H3 receptor: an attractive target for the
22 treatment of cognitive disorders. *Brit. J. Pharmacol.* 154, 1166–1181
- 23 77. Hirst, W.D. et al. (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist
24 with cognitive enhancing properties in aged rat water maze and novel object
25 recognition models. *Eur. J. Pharmacol.* 553, 109–119

26

1 **Table 1.** Mechanisms of action found effective in two animal assays: scopolamine-induced amnesia in
 2 the passive avoidance paradigm and delay-induced („natural”) forgetting in the novel object
 3 recognition test. Findings are from a PubMed search, the terms were „passive avoidance AND
 4 scopolamine AND [rats OR mice]” and „novel object recognition AND [delay OR retention] AND [rats
 5 OR mice]”. Bolded are the mechanisms in clinical use. The table shows some peculiarities, such
 6 as: i) antagonists as well as agonists of the 5-HT_{1A}, GABA-A, GABA-B, NMDA, opioid
 7 receptors were found to be effective; ii) almost all types of selective phosphodiesterase
 8 inhibitors showed activity; iii) nearly each serotonin receptor subtype emerged as
 9 procognitive target; iv) the enormously high number of herbal cognitive enhancers – a rich
 10 source for designing new multitarget drugs.

11 78.

Targets effective in passive avoidance – scopolamine assay	Targets effective in novel object recognition – natural forgetting assay
„-racetams”	1. „-racetams”
5-HT _{1A} agonist	2.
5-HT _{1A} antagonist	3. 5-HT _{1A} antagonist
5-HT _{1B} antagonist	4.
	5. 5-HT _{2A} agonist
5HT _{2C} antagonist	6. 5-HT _{2C} inverse agonist/antagonist
5-HT ₃ antagonist	7. 5-HT ₃ antagonist
5-HT ₄ agonist	8. 5-HT ₄ agonist
5-HT ₆ antagonist	9. 5-HT ₆ antagonist
	10. 5-HT ₇ agonist
A ₁ (adenosine receptor) antagonist	11.
	12. A ₂ (adenosine receptor) antagonist (caffeine)
A ₃ (adenosine receptor) agonist	13.
ACE (angiotensin converting enzyme) inhibitor	14.
ACh (acetylcholine) releaser	15.
AChE (acetylcholine-esterase) inhibitor	16. AChE (acetylcholine-esterase) inhibitor
adrenerg α ₂ antagonist	17. adrenerg α ₂ antagonist
	18. adrenerg β agonist
agmatine	19.
AMPA receptor positive modulators	20. AMPA receptor positive modulators
antioxidants	21.
	22. APP ^S (secreted amyloid precursor protein)
AT ₁ (angiotensin receptor) antagonist	23.
AT ₂ (angiotensin receptor) agonist	24.
AT ₄ (angiotensin receptor) agonist	25.
AVP (arginine vasopressin)	26.
BDNF signalling activation	27.
BZD (benzodiazepine) inverse agonist/antagonist	28.
Ca ²⁺ -channel inhibitor	29.
	30. CB1 (cannabinoid receptor) antagonism
CCK (cholecystokinin) agonist	31.
complement C3a agonist	32.
COMT (catechol-O-methyltransferase) inhibitor	33.
cyclooxygenase inhibitor	34.
D ₁ dopamine agonist	35. D ₁ dopamine agonist
D ₂ dopamine agonist	36. D ₂ dopamine agonist
D ₃ dopamine antagonist	37. D ₃ dopamine antagonist
DARI (dopamine reuptake inhibitor)	38.
DHEA(S) (dihydroepiandrosteron-sulphate)	39.
ergot alkaloids	40.
	41. erythropoiesis
estrogen	42. estrogen
GABA uptake inhibitor	43.

GABA-A agonist / positive modulators	44.	
GABA-A antagonist	45.	GABA-A antagonist
GABA-B agonist	46.	
GABA-B antagonist	47.	
GABA α 5 inverse agonist	48.	GABA α 5 inverse agonist
gastrin releasing peptide	49.	
	50.	glutamate carboxypeptidase II inhibitor
glutamate derivatives	51.	
GM1 ganglioside	52.	
	53.	GnRH (gonadotropin releasing hormone)
H ₁ (histamine receptor) agonist	54.	
H ₃ (histamine receptor) antagonist	55.	H ₃ (histamine receptor) antagonist
H ₄ (histamine receptor) agonist	56.	
	57.	histone deacetylation in the BLA
HDAC (histone deacetylase) inhibitor	58.	
HMG-CoA inhibitor (atorvastatin)	59.	
IL-1 α (interleukin)	60.	
IL-6 (interleukin)	61.	
insulin	62.	
K ⁺ -channel inhibitor	63.	K ⁺ -channel inhibitor
M ₁ (muscarinic receptor) agonist	64.	
M ₂ (muscarinic receptor) antagonist	65.	
MAO (monoamine-oxidase) inhibitor	66.	
melatonin receptor agonist	67.	
	68.	mGluR2/mGluR3 antagonist
NAA (N-acetyl-aspartate)	69.	
NGF (nerve growth factor)	70.	
	71.	nicotinic α 4 β 2 agonist
nicotinic α 7 agonist	72.	nicotinic α 7 agonist
NMDA antagonist	73.	NMDA antagonist
NMDA glycine site agonist	74.	NMDA glycine site agonist
NMDA polyamine site agonist	75.	
	76.	NO (nitric oxide) donor
	77.	NOS (nitric oxide synthase) inhibitor
	78.	neurokinin 3 agonist
NPY (neuropeptide Y) agonist	79.	
	80.	neuropeptide S
	81.	neuropeptide Trefoil factor 3
opioid receptor agonist (morphine)	82.	
opioid receptor antagonist (naloxone)	83.	
opioid κ receptor agonist	84.	
ORL-1 (orphanine receptor) agonist (low dose)	85.	
ORL-1 (orphanine receptor) antagonist	86.	
	87.	PDE-1 (phosphodiesterase) inhibitor
	88.	PDE-2 (phosphodiesterase) inhibitor
	89.	PDE-3 (phosphodiesterase) inhibitor
PDE-4 (phosphodiesterase) inhibitor	90.	PDE-4 (phosphodiesterase) inhibitor
	91.	PDE-5 (phosphodiesterase) inhibitor
PDE-9 (phosphodiesterase) inhibitor	92.	PDE-9 (phosphodiesterase) inhibitor
	93.	PDE-10 (phosphodiesterase) inhibitor
PEP (prolyl-endopeptidase) inhibitor	94.	
PPAR γ agonist	95.	
pregnenolon sulphate	96.	
retinoid Am80 (RAR/RXR agonist)	97.	
sigma-1 agonist	98.	
somatostatin	99.	
SRI (serotonin reuptake inhibitor)	100.	SRI (serotonin reuptake inhibitor)
steroid sulphatase inhibitor	101.	
TRH (thyrotropin releasing hormone) agonist	102.	
	103.	vasopressin 1b antagonist
+ ca. 100 types of herbal extracts or derivatives		

- 1 79.
- 2 80.
- 3 81.
- 4 82.
- 5

1

Table 2. Human cognitive domains and their suggested animal models

cognitive domain	animal assay	reference ^a
working memory	delayed non-matching to sample	[38]
semantic memory	Morris water-maze (allocentric navigation)	[47]
episodic memory	multiple T-maze (egocentric navigation)	[47]
visual memory	touchscreen paired associates learning	[48]
attention & information processing	5-choice serial reaction time task	[40]
	prepulse inhibition	[49]
fear extinction	fear conditioning	[50]
social cognition	social recognition / preference	[37]
executive function	rule learning	attentional set shifting [39]
	decision making	probabilistic reward learning [51]
	response inhibition	delayed reinforcement of low rate [52]
procedural memory	rotarod learning	[53]

2

a: the reference papers not only describe the particular assay but also discuss its theoretical background

3

1 **Box 1**

2 **Disease modifying vs symptomatic treatment for cognitive disorders**

3 Disease modifying treatment, which would be the ideal case, relies on our knowledge on the
4 pathomechanism of the disease. The Achilles-heel of any disease modifying approach is the
5 soundness and validity of the underlying hypothesis on the pathomechanism, which can
6 ultimately be checked only in the target patient population.

7 In Alzheimer disease, such a strong theory has been the amyloid cascade hypothesis [54,56].
8 Accordingly, transgenic mouse models based on the familial form of the disease and
9 characterized by massive human β -amyloid overproduction formed the key assays in drug
10 testing. However, these animals were much more a model of amyloid intoxication than a
11 model of the disease itself: they lacked tau pathology and the cognitive deficits were
12 discrepant and uncorrelated to the histological changes [57,58,59,60]. The serial failures of
13 the subsequent clinical trials severely punished the overlooking of these caveats of the animal
14 model [61,62] and raised serious doubts about the validity/soundness of the amyloid theory
15 [63,64,65].

16 In psychiatric disorders the etiological theories are even weaker than in AD as very little is
17 known on the underlying mechanisms of defective cognitive functions. For example,
18 according to the glutamatergic hypothesis of schizophrenia, cortical NMDA glutamate
19 receptor hypofunction plays a central role in the pathomechanism [66]. In harmony with this,
20 subchronic phencyclidine (PCP) treatment induced alterations are widely accepted as a model
21 of glutamatergic dysfunction in schizophrenia [67]. However, a recent review demonstrated
22 that this model is far from being able to recapitulate all the relevant cognitive deficits of the
23 disease [68] pointing out some shortcomings of the theory and/or the model. Even more
24 problematically, subchronic PCP-induced learning/memory impairments were reported to be
25 restored by several atypical antipsychotics [69,70]. These findings are in sharp contrast to the
26 clinical experience where these drugs are not particularly reputed for their memory improving
27 properties. The model thus lacks specificity and may detect false positive compounds.

28 Symptomatic treatment offers a lower risk – lower benefit alternative. It is based on activating
29 more or less non damaged compensatory cognitive enhancer mechanisms and may feasibly be
30 developed without exact knowledge on the etiology of the disease. The distinct cognitive
31 symptoms (domains) can be modelled and examined separately. On the other hand, a single
32 cognitive enhancer mechanism, be it so potent, cannot compensate for all the complex deficits

1 of the disorder generated by malfunctions in multiple pathways in the central nervous system.
2 Therefore, the therapeutic effect achievable via the symptomatic approach is predictably less
3 robust as demonstrated e.g. by the acetylcholinesterase inhibitors [3]. However, augmenting
4 the points of symptomatic interventions by combining 2-3 validated targets either via
5 combination therapy or multitarget directed ligands may result in activity on more symptoms
6 and/or higher effect size.

7

8 **Box 2**

9 **Changing the drug discovery paradigm**

10 As the pattern-matching approach implies elevated requirements for a certain mechanism or
11 compound for being deemed “efficacious”, the number of real hits will foreseeably be
12 reduced. It may be considered good news on one hand, as the basic translational problem was
13 the high number of false positive hits in the animal literature. On the other hand, because of
14 the scarcity of compounds capable to enter clinical trials and the longer preclinical
15 investigation periods it is also foreseeable that industrial investors and top management may
16 easily become disappointed and decide to refrain from CNS drug development – as it already
17 happened in the near past. Experience shows that the described target validating
18 experimentation does not fit the industrial R&D timeframe and scenery. Therefore, it should
19 be done in the precompetitive area and outside of the conventional industrial settings. Once
20 the target is (deemed to be) valid, drug discovery screening may return to its traditional way,
21 back to the companies’ R&D labs, and can be carried out in simple(r) assays with sufficient
22 robustness and capacity. Before entering into developmental phase with the optimized
23 molecule, the selected clinical candidate could be checked again in the target validating
24 paradigms. The study could be considered as a kind of early proof of concept trial and would
25 conform to the ‘fail fast’ (and cheap...) developmental strategy [71].

26 However, carrying out all the assays of Table 1 requires a large amount of effort and time and
27 collaboration among labs (see Outstanding Questions). A complete target validation may well
28 be realized within a couple of years. Not a short period, but *a)* it’s still much less than the time
29 lost in late clinical phases because of the recurrent trial failures and *b)* it’s an investment with
30 high return: a recent analysis [71] pointed out that Phase 2 and 3 success probabilities are the
31 two most important determinants of overall R&D efficiency, and decreasing the
32 corresponding attrition rates by 1/4 and 1/3, respectively, may lead to a 1/3 decrease in the

1 average capitalized cost of a launch. With regard to the high societal needs for novel cognitive
2 therapies, the long history of unsuccessful attempts and the collaborative nature of the job,
3 this kind of target validation activity should obviously be supported by dedicated research
4 funding.

5

6

7 **Glossary**

8 **allocentric navigation** “is characterized by the ability to navigate using distal cues, i.e., cues
9 located outside and at some distance from the organism (e.g., landmarks).” (cited from [47])

10 **attrition rate** in clinical development: the ratio between the number of compounds failed in
11 the clinical trials and the number of all tested compounds. Attrition rate can also be calculated
12 for clinical trials instead of compounds in a similar way. While the former demonstrates the
13 net success rate of clinical development, the latter, which results in higher figures, rather
14 reflects the efforts and costs of the development.

15 **CNTRICS initiative:** Cognitive Neuroscience Treatment Research to Improve Cognition in
16 Schizophrenia. “... focused on ... the identification of cognitive ‘constructs’ – definable
17 cognitive processes that can be measured at the behavioral level and for which there exist
18 clearly hypothesized and measureable neural-circuit mechanisms. ... yielding a scheme of
19 cognitive domains, and within each domain specific constructs considered to be most relevant
20 to the cognitive impairments of schizophrenia. ... to develop cognitive neuroscience
21 paradigms for use in humans that could selectively and parametrically measure these
22 constructs at the behavioral level ... In a second phase ... to further develop homologous
23 assays of the key cognitive constructs within biomarker studies and animal model systems.”
24 (cited from [36])

25 **declarative memory:** explicit, conscious memory on facts, events and concepts. It can be
26 divided to semantic and episodic memory (see below)

27 **disease modifying treatment:** treatment which results in change in the course of the disease
28 process: slowing down, halting or even reversing it. It assumes the pathomechanism of the
29 disease is known to the degree that enables us to directly intervene in the pathological events.

30 **egocentric navigation** “is characterized by the ability to find one's way using internal and/or
31 near (proximal) cues. Internal cues include proprioceptive feedback from limb/joint receptors

1 and stretch receptors in muscles and tendons that provide a sense of speed of motion that,
2 when combined with heading or directional information and signposts about which way to
3 turn, produce a pathway or route to and from different locations.” (cited from [47])

4 **episodic memory** refers to the memory of our experiences and events happened with us in the
5 past and also to the ability to position ourselves in time and space; e.g. when and where my
6 first date was

7 **executive function:** “A purposeful, goal-directed operation such as planning, decision
8 making, problem solving, reasoning, concept formation, self-monitoring or cognitive
9 flexibility (adaptive alternation between different strategies, responses and behaviours).”
10 (cited from [34])

11 **external validity:** with regard to animal models of human diseases external validity refers to
12 the “goodness”, reliability, precision of inferences which can be drawn from the model onto
13 to the disease. It is usually decomposed to predictive (specificity and sensitivity), face and
14 construct validity (fidelity of the model).

15 **fear extinction:** pairing non-aversive contextual or discrete cues (conditioned stimulus) to a
16 fear-provoking aversive (unconditioned) stimulus results in long-lasting fear responses to the
17 formerly neutral stimulus, termed conditioned fear. The acquired fear responses can undergo
18 extinction when the subject recognizes the fear-provoking stimulus is no more coupled to the
19 conditioned stimulus. Fear extinction is an active learning process which is damaged in post-
20 traumatic stress disorder.

21 **internal validity:** it reflects those features of a model which enable us to draw solid
22 conclusions on the causal relationships between phenomena studied in the model. Such
23 features are e.g. reliability, reproducibility, robustness, stability, accuracy.

24 **MATRICES initiative:** Measurement of Treatment Effects on Cognition in Schizophrenia,
25 initiative of the NIMH with the goal to identify the core cognitive deficits of schizophrenia
26 and to develop a standardized test battery for their measurement (MATRICS Consensus
27 Cognitive Battery). The work continued in the CNTRICS initiative.

28 **procedural memory:** implicit, unconscious memory of motor skills, e.g. how to ride a bike

29 **proof of concept trial:** a clinical investigation aiming at proving/confirming the scientific
30 hypothesis set on the relationship between drug effect on a given target and disease outcome.
31 Phase 2 trials where the efficacy of a drug is first tested on a smaller number of patients

1 traditionally belong to this category. Recently, certain biomarker studies carried out on non-
2 patient subjects may also be considered as proof of concept trials.

3 **response inhibition:** the ability of the subject to withhold a formerly reinforced or otherwise
4 advantageous “prepotent” response in order to achieve a more favourable goal. Impaired
5 response inhibition is a key component of impulsivity.

6 **semantic memory** refers to the memory of facts, objects, ideas; our lexical knowledge; e.g.
7 how big an apple can be.

8 **social cognition** “refers to processes used to monitor and interpret social signals from others,
9 to decipher their state of mind, emotional status and intentions, and select appropriate social
10 behaviour.” (cited from [37])

11 **symptomatic treatment:** treatment which only modifies the symptoms of a disease
12 (diminishing or abolishing them) without affecting the pathological sequel. Symptomatic
13 treatment is usually based on activating non damaged compensatory cognitive enhancer
14 mechanisms.

15 **theory of mind** refers to the ability to make inferences on someone else’s mental state
16 (thoughts, emotions or intentions) and prediction of his/her future behaviour based on social
17 signals and the context of the situation.

18 **working memory:** in animals, the term refers to short-term storage of information which can
19 subsequently be transferred to long-term memory stores or dropped (forgotten) if it is no more
20 needed. In humans the term covers a more complex process, including also certain computing
21 activities (“working”) with the stored items.

22

1 **Figure legends**

2 **Figure 1. A rodent test battery for characterizing potential cognitive enhancer**
3 **compounds.**

4 The leftmost column lists assays modelling certain cognitive functions (see Table 1). Other
5 columns represents various impairment methods, thus each cell in the table corresponds to a
6 particular cognitive deficit model. Shading and symbols in the table illustrate hypothetical
7 activity patterns as follows: unshaded and shaded cells indicate impaired and unimpaired
8 cognitive performance, respectively, obtained after applying a concrete type of the impairing
9 method in the column header. Each column has a particular impairment pattern representing a
10 certain “disease state”. Symbols show the cognitive improving effects of two compounds,
11 Compound Red and Compound Pink, with distinct mechanisms of action; the latter tested in
12 only two “disease states”. 0: no effect, x or +: mild effect; xx or ++: moderate effect; xxx or
13 +++: strong effect. The “results” demonstrate that 1. a compound may have different actions
14 on the different cognitive defects (symptoms) in a given “disease state”; 2. it may have
15 different activity profile in different “disease states”; 3. a particular “disease state” (e.g. old
16 age or stress-induced) may be differently affected by different types of compounds; 4. the
17 resulting outcome of testing a particular cognitive enhancer mechanism is a cognitive
18 enhancer pattern

19 Abbreviations: PAL: paired associates learning; 5-CSRTT: 5-choice serial reaction time task;
20 PPI: prepulse inhibition; DRL: delayed reinforcement of low rate. For further information on
21 the assays see the references of Table 1.

22

Outstanding questions:

- What degree of pattern similarity would suffice for a go decision?
- How many and how large positive effects can be considered sufficient?
- Which has more bearing: effects on many cognitive domains or against many impairments?
- Can weaker efficacy be compensated by a more widespread activity profile and vice versa?
- What if the results with different “probes” of the same mechanism (e.g. two different compounds with similar mode of action) do not converge?
- What if the results in different models of the same cognitive domain (e.g. two different episodic memory models) do not converge?
- Where is the optimal place of target validation activity in the drug discovery/development process?
- What is the time frame of validating a single molecular target?
- How many labs should be involved in a target validating collaboration?
- How should methodical coherence be assured among the collaborating labs?
- Who should fund the work?

Figure 1. A rodent test battery for characterizing potential cognitive enhancer compounds.

The leftmost column lists assays modelling certain cognitive functions (see Table 1). Other columns represents various impairment methods, thus each cell in the table corresponds to a particular cognitive deficit model. Shading and symbols in the table illustrate hypothetical activity patterns as follows: unshaded and shaded cells indicate impaired and unimpaired cognitive performance, respectively, obtained after applying a concrete type of the impairing method in the column header. Each column has a particular impairment pattern representing a certain „disease state”. Symbols show the cognitive improving effects of two compounds, Compound Red and Compound Pink, with distinct mechanisms of action; the latter tested in only two „disease states”. 0: no effect, x or +: mild effect; xx or ++: moderate effect; xxx or +++: strong effect. The „results” demonstrate that 1. a compound may have different actions on the different cognitive defects (symptoms) in a given „disease state”; 2. it may have different activity profile in different „disease states”; 3. a particular „disease state” (e.g. old age or stress-induced) may be differently affected by different types of compounds; 4. the resulting outcome of testing a particular cognitive enhancer mechanism is a cognitive enhancer pattern.

Abbreviations: PAL: paired associates learning; 5-CSRTT: 5-choice serial reaction time task; PPI: prepulse inhibition; DRL: delayed reinforcement of low rate. For further information on the assays see the references of Table 1.

animal assay	cognitive deficit induced by						
	drug treatment	lesion/activation	stress	modulation of gene expression	old age	task difficulty	segmenting the performer population
delayed non-matching to sample	x	0	0 0	0	0 +	x	0
Morris water-maze	xxx				xx ++	xxx	
multiple T-maze					xxx 0	xx	
touchscreen PAL		xx	xx ++			0	x
5-CSRTT	0	0	0 ++		0 +	x	x
PPI			x +		0 0		0
fear conditioning			0 0				0
social recognition						x	
attentional set shifting	0		x +	0	x ++	0	x
probabilistic reward learning	0		0 0	0	0 0	0	x
DRL			0 0			0	x

rotarod learning	xx				0 0	0	0
------------------	----	--	--	--	-----	---	---